Pharmaxis CEO Gary Phillips said, “The agreement with the FDA to expand the patient population in the ongoing Phase 2 study to include those patients currently on a JAK inhibitor is an important step forward in realising the benefits of lysyl oxidase inhibition for all myelofibrosis patients and in maximising the commercial opportunity for PXS‐5505." …
Latest Video
New Stories
-
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News -
The minister and the US-based industry have a lot in common, including their criticisms of the PBS
March 20, 2025 - - Latest News -
Sigma releases final pre-merger full-year result, confirming impact of CW supply contract
March 20, 2025 - - Latest News -
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News